FINANCIAL NEWS

Abu Dhabi’s Proteus profit up to USD172m

01 Aug 2014

(MENAFN) A US biotech company pioneering tablets containing embedded microchips that can tell if patients have taken their medication said it has raised a further USD172 million, including funds from a firm part-owned by Abu Dhabi”s Mubadala Development Company, according to Arabian Business.

Privately held Proteus Digital Health, which is working with drugmakers including Novartis and Otsuka, said this week the funding was one of the biggest US private financings this year and the largest in the digital health sector and shows investor interest in its ingestible and wearable technology.

Proteus already has European and US approval for its “smart pill” technology system, in which a tiny sensor is embedded in a tablet and linked to a patch worn on the patient’s abdomen.

More News

This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more